Advanced search
1 file | 611.82 KB Add to list

Chemotherapy at the wheel of ALL relapse

(2020) BLOOD. 135(1). p.3-5
Author
Organization
Abstract
In this issue of Blood, Li et al(1) present an extensive in-depth genetic characterization of diagnostic, relapse, and remission samples from a cohort of 103 pediatric patients with acute lymphoblastic leukemia (ALL) treated according to the Shanghai Children's Medical Center ALL-2005 frontline protocol. Together with data obtained from 208 serial bone marrow samples collected during ALL therapy, their work suggests that relapse in a fraction of childhood ALL patients is driven by chemotherapy-induced mutations, which impact therapy response.
Keywords
T-CELL, RESISTANCE

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 611.82 KB

Citation

Please use this url to cite or link to this publication:

MLA
Morscio, Julie, and Pieter Van Vlierberghe. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD, vol. 135, no. 1, 2020, pp. 3–5, doi:10.1182/blood.2019003870.
APA
Morscio, J., & Van Vlierberghe, P. (2020). Chemotherapy at the wheel of ALL relapse. https://doi.org/10.1182/blood.2019003870
Chicago author-date
Morscio, Julie, and Pieter Van Vlierberghe. 2020. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD. https://doi.org/10.1182/blood.2019003870.
Chicago author-date (all authors)
Morscio, Julie, and Pieter Van Vlierberghe. 2020. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD. doi:10.1182/blood.2019003870.
Vancouver
1.
Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. Vol. 135, BLOOD. 2020. p. 3–5.
IEEE
[1]
J. Morscio and P. Van Vlierberghe, “Chemotherapy at the wheel of ALL relapse,” BLOOD, vol. 135, no. 1. pp. 3–5, 2020.
@misc{8665841,
  abstract     = {{In this issue of Blood, Li et al(1) present an extensive in-depth genetic characterization of diagnostic, relapse, and remission samples from a cohort of 103 pediatric patients with acute lymphoblastic leukemia (ALL) treated according to the Shanghai Children's Medical Center ALL-2005 frontline protocol. Together with data obtained from 208 serial bone marrow samples collected during ALL therapy, their work suggests that relapse in a fraction of childhood ALL patients is driven by chemotherapy-induced mutations, which impact therapy response.}},
  author       = {{Morscio, Julie and Van Vlierberghe, Pieter}},
  issn         = {{0006-4971}},
  keywords     = {{T-CELL,RESISTANCE}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{3--5}},
  series       = {{BLOOD}},
  title        = {{Chemotherapy at the wheel of ALL relapse}},
  url          = {{http://dx.doi.org/10.1182/blood.2019003870}},
  volume       = {{135}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: